LON:HCM - HUTCHMED Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 220
  • Forecasted Upside: -12.70 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 252
▲ +10 (4.13%)

This chart shows the closing price for HCM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New HUTCHMED Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HCM

Analyst Price Target is GBX 220
▼ -12.70% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for HUTCHMED in the last 3 months. The average price target is GBX 220, with a high forecast of GBX 0 and a low forecast of GBX 0. The average price target represents a -12.70% upside from the last price of GBX 252.

This chart shows the closing price for HCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in HUTCHMED. This rating has held steady since July 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/23/2022CitigroupReiterated RatingBuyGBX 220
7/15/2020BarclaysReiterated RatingEqual weight
12/11/2019Morgan StanleyInitiated CoverageEqual weightGBX 360
3/27/2019HSBCInitiated CoverageBuyGBX 5,940
2/14/2018Beaufort SecuritiesReiterated RatingBuy
8/29/2017Panmure GordonReiterated RatingBuyGBX 3,840
8/1/2017Beaufort SecuritiesReiterated RatingBuy
(Data available from 7/6/2017 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/7/2022
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/6/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/8/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/7/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/7/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/6/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/6/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
HUTCHMED logo
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Read More

Today's Range

Now: GBX 252
Low: 220
High: 260

50 Day Range

MA: GBX 184.29
Low: 144
High: 252

52 Week Range

Now: GBX 252
Low: 137.80
High: 633

Volume

250,240 shs

Average Volume

115,277 shs

Market Capitalization

£2.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of HUTCHMED?

The following sell-side analysts have issued stock ratings on HUTCHMED in the last year: Citigroup Inc..
View the latest analyst ratings for HCM.

What is the current price target for HUTCHMED?

0 Wall Street analysts have set twelve-month price targets for HUTCHMED in the last year. Their average twelve-month price target is GBX 220, suggesting a possible downside of 12.7%.
View the latest price targets for HCM.

What is the current consensus analyst rating for HUTCHMED?

HUTCHMED currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HCM will outperform the market and that investors should add to their positions of HUTCHMED.
View the latest ratings for HCM.

How do I contact HUTCHMED's investor relations team?

The company's listed phone number is +85221213888. The official website for HUTCHMED is www.chi-med.com. Learn More about contacing HUTCHMED investor relations.